Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07399327

Biomarkers of Response to SEEG Thermocoagulation

Biomarkers of Response to SEEG Thermocoagulation in Patients With Refractory Focal Epilepsy

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
45 (estimated)
Sponsor
Assistance Publique Hopitaux De Marseille · Academic / Other
Sex
All
Age
12 Years
Healthy volunteers
Not accepted

Summary

Drug-resistant focal epilepsy is a severe neurological disease that affects one-third of patients with epilepsy. Surgery is the only potentially curative treatment. Intracerebral exploration by stereo electroencephalography (SEEG) is an important step in the surgical pathway. It aims to establish the precise mapping of the epileptogenic network (EZN), including all the brain regions that generate seizures. At the end of SEEG, SEEG-guided radiofrequency thermocoagulation (SEEG RFTC) represents a therapeutic option that may be efficient as a palliative treatment in patients ineligible for resective surgery, or may lead, in some cases, to a definitive effect, avoiding open surgery. The safety and effectiveness of this approach have been established. However, the odds of remaining seizure-free after one year vary greatly between studies, ranging from 4% to 71%. This disparity in therapeutic responses could be linked to the absence of objective criteria for the selection of targets, but also to the existence of mechanisms of action outside of the direct lesional effect. A decrease in SEEG markers of epileptogenicity may predict thermocoagulation efficiency. However, no data are available regarding changes in alteration of the blood-brain barrier (BBB) connectivity, inflammation, or associated molecular changes and their relationship to prognosis. This study aims to elucidate the mechanisms underlying the clinical effect of SEEG RFTC by studying the changes in electrophysiological (SEEG), structural (ultra-high field MRI), and biological (blood biomarkers of neuro-glio-vascular damage and inflammation, molecular adaptations) markers. They will be correlated with clinical outcome in a prospective cohort of patients with drug-resistant focal epilepsy. As advantages for clinical care, this study will allow selection of RFTC targets based on scientifically validated criteria, and elaboration of predictive scores for therapeutic response in each patient. The primary objective is to study the predictive factors of response to SEEG RFTC, by correlating changes in BBB permeability with clinical response 3 months after RFTC, in a prospective cohort of patients with drug-resistant focal epilepsy.

Conditions

Interventions

TypeNameDescription
OTHERQuality of life questionnaires (QOLIE, EFIQUACEE for children), psychiatric questionnaires (NDDIE, GAD-7, PCL-5) at Visit 1 (V1), V5, V6 and V7This intervention consists in the completion of diverse questionnaires assessing the quality of life of the subject. These questionnaires include: * quality of life questionnaires: QOLIE or EFICACEE for children * psychiatric questionnaires NDDIE, GAD-7, PCL-5 These questionnaires will be performed during V1, V5, V6 and V7
OTHERResting state SEEG recording 30min before and 30 min after RFTCDuring this intervention a resting state SEEG recording will be performed before and after RFTC. These recordings will last for 30 minutes each.
OTHERBlood sample at Visit 1 (V1), V2, V4 and V5Blood samples will be collected at Visit 1 (V1), V2, V4 and V5. 2 tubes of 2 ml EDTA will be collected during these visits
OTHERSEEG electrodes tissue-traces sample at V3 (during SEEG electrodes ablation)During this intervention, investigators will collect brain tissue samples on SEEG electrodes during their extraction.
OTHERMultiparametric 3T MRI with gadolinium at V1, V4 and V53T MRI with gadolinium injections will be performed at V1, V4 and V5.
OTHERMultiparametric 7T MRI at V1 and V5Patients will undergo 7T MRI at V1 and V5

Timeline

Start date
2026-03-01
Primary completion
2029-01-31
Completion
2029-06-30
First posted
2026-02-10
Last updated
2026-02-10

Source: ClinicalTrials.gov record NCT07399327. Inclusion in this directory is not an endorsement.